RxDoctor Payments Data

Yong Kwon, MD

Gastroenterology · Glen Ridge, NJNPI 1528186384

Payments from drug & device makers

$3,331in general payments, 2019–2025

Across 168 payments — averaging $19.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$780
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$400
  • Sanofi$303
  • Takeda Pharmaceuticals U.S.A., Inc.$303
  • Pfizer$233
  • Bristol Myers Squibb$217
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$3,30799%
  • Education$241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,331 in reported general payments places this provider in the 55th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$157,144
Medicare patients
380
Services billed
3,157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide39$39,009
CreonLipase/Protease/Amylase19$27,549
Mesalamine21$14,262
MotegrityPrucalopride Succinate12$6,197
Mesalamine ErMesalamine11$2,614
Pantoprazole Sodium142$2,295
Colestipol Hcl28$2,254
Famotidine133$2,180
Omeprazole125$1,942
Esomeprazole Magnesium43$1,570
Dicyclomine Hcl39$1,027
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine26$644
Hydrocortisone11$104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$780$66,55858 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$303$6,19712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in Glen Ridge

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →